RESULTS: The mean ages of the three groups were 53.2 AE 7.7, 56.1 AE 8.1, and 55.3 AE 7.1 years, respectively. No differences in age, erectile function, or duration and characteristics of PD were observed among the groups at baseline. Pain resolution was achieved in 55%, 70%, and 78.3% of patients in the groups after 12 weeks (p < 0.01). The changes in the mean degree of curvature were -4.6 AE 3.2, -6.2 AE 4.4, and -7.2 AE 4.5 in the groups (p < 0.01). The changes in mean plaque size were 0.2 AE 0.1, 0.2 AE 0.2, and 0.3 AE 0.2 cm2 in the groups (p < 0.01). Groups 2 and 3 showed a greater increase in the International Index of Erectile Function-erectile function domain score (0.4 AE 0.8, 3.8 AE 1.2, and 3.8 AE 1.3; p < 0.01) than that in group 1. Commonly reported adverse treatment events were hematoma at the injection site (four cases), myalgia (three cases), and dyspepsia, headache, and flushing (one case each); however, no patient discontinued treatment due to adverse events.
INTRODUCTION AND OBJECTIVES:
Dutasteride has a uniquely long half-life of 35 days which offers a theoretical advantage as a chronic therapy for management of stuttering priapism. The objective of this study is to review our 12 year experience with the 5-a reductase inhibitor dutasteride as a potential long term treatment option for stuttering priapism.
METHODS: We retrospectively reviewed patients with stuttering priapism in our database from 2006-2018 that were treated with dutasteride. Men with concurrent use of medications other than dutasteride to treat stuttering priapism were excluded. Patients were started on a dose of 0.5 mg daily and tapered to a more infrequent dosing schedule, ranging from 0.5 mg every other day to once weekly. Outcomes analyzed were the frequency of stuttering priapism episodes before and after initiation of dutasteride therapy.
RESULTS: Among 21 cases, 13 patients met our inclusion criteria (mean age 43 years). Median follow-up on daily dutasteride was 79 days and mean follow-up on tapered dutasteride was 607 days. A total of 11/13 (85%) men treated with dutasteride had some degree of improvement -5/13 (38%) had complete resolution of their symptoms and 6/13 (46%) had reduced frequency and/or severity of their episodes. Among 5/13 (38%) men who had >2 ER visits for ischemic priapism prior to therapy, most (3/5, 60%) did not require any ER visits while on dutasteride therapy. All five men receiving chronic, tapered-dose therapy reported continued suppression of priapistic episodes. In patients with sickle cell disease, 75% (3/4) ultimately chose more invasive therapy including ADT and penile prosthesis. Side effects were minimal and included gynecomastia (7%), decreased libido (7%), and fatigue (7%).
CONCLUSIONS: In patients with stuttering priapism, daily dutasteride therapy is a promising treatment option to reduce the frequency and severity of stuttering episodes of priapism without a significant side effect profile. Therapy can effectively be tapered to once weekly dosing without a reduction in efficacy. METHODS: PCs were harvested from mouse corpus cavernosa and cultured. The cell suspension was sequentially extruded through ultrafine filtering and two-step OptiPrep gradient technique to acquire purified exosomes as nanovesicles. Diabetes was induced by intraperitoneal injection of streptozotocin into 8-week-old C57BL/6 male mice. At 8 weeks after the induction of diabetes, the animals were distributed into 3 groups: control nondiabetic mice and diabetic mice receiving two successive intracavernous injections of PBS (days -3 and 0; 20 mL or PC-derived exosome (days -3 and 0; 5 mg in 20 mL of PBS). Two week after treatment, we measured erectile function by electrical stimulation of the cavernous nerve. The penis was harvested and stained with antibodies to PECAM-1, smooth muscle a-actin, NG2, and bIII-tubulin. We also determined angiogenic potential of PC-derived exosome in an ex vivo aortic ring assay and in primary cultured mouse cavernous endothelial cell (MCEC) and pericyte (MCP) mono-culture or co-culture system in vitro.
RESULTS: Intracavernous injections of PC-derived exosome significantly improved erectile function in diabetic mice, which reached up to 91% of control values. PC-derived exosome induced significant restoration of cavernous contents of endothelial cells, smooth muscle cells, pericytes, and neuronal cells in diabetic condition. Moreover, PC-derived exosome promoted microvascular sprouting from aortic ring and accelerated tube formation in primary cultured MCEC and MCP mono-culture or co-culture system in vitro.
CONCLUSIONS: PC-derived exosome successfully restored erectile function through enhanced cavernous angiogenesis and neural regeneration in diabetic mice. Intracavernous delivery of exosomes derived from cavernous tissue can be a good strategy for the treatment of intractable ED in a near future.
